EMA backs approval of key drugs from Celgene and Aegerion

Ryan McBride

Two drugmakers reported regulatory victories for therapies in the important European market. A European Medicines Agency committee endorsed of 's ($ CELG) pomalidomide for multiple myeloma and 's ($ AEGR) Lojuxta for a genetic cause of high cholesterol called homozygous familial hypercholesterolemia.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS